Somatropin - Novo Nordisk

Drug Profile

Somatropin - Novo Nordisk

Alternative Names: NN-1610; NN-220; Norditropin; Norditropin cartridge; Norditropin FlexPro; Norditropin NordiFlex; Norditropin NordiLet; Norditropin NordiPen; Norditropin S; Norditropin SimpleXx; Somatotropin - Novo Nordisk

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novo Nordisk
  • Class Growth hormones; Hormonal replacements
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Short stature; Female infertility; Somatotropin deficiency
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Dwarfism; Growth disorders; Short stature; Somatotropin deficiency
  • Discontinued Female infertility; Fracture; Nutrition disorders

Most Recent Events

  • 01 Apr 2016 Final adverse events and efficacy data from a phase III trial in Idiopathic short stature presented at the The 98th Annual Meeting of the Endocrine Society (ENDO-2016)
  • 26 Jan 2015 The US FDA approves Norditropin® FlexPro® (somatropin [rDNA origin] injection, 30 mg/3.0ml) for treatment of Somatotropin deficiency in USA
  • 05 Feb 2014 Novo Nordisk completes enrolment in its phase III trial for Short stature (idiopathic, in children) in South Korea (NCT01778023)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top